Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 26, 2015 8:18 AM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Torsgatan 11

Stockholm,  111 23

Sweden

Founded in 2005

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Founder, Chief Executive Officer, President, Managing Director, Member of the Management Group and Director
Age: 40
Chief Financial Officer and Member of the Management Group
Age: 43
Member of the Management Group and Chief Executive Officer of Bluefish Global Technology Center
Age: 55
Head of development and Quality Assurance
Director of Bluefish India office
Compensation as of Fiscal Year 2014.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals AB Provides Earnings Guidance for the Year 2015

Bluefish Pharmaceuticals AB provided earnings guidance for the year 2015. For the year, The company expects that net sales in 2015 will grow. The increase will come from already secured tenders, planned new product launches as well as a general increase in market share. The expansion in gross margin is expected to continue, however, not in parity with that of the fourth quarter of 2014. With an expected increase in revenues, together with an expansion of the gross margin, The company anticipates a positive EBITDA in 2015.

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Bluefish Pharmaceuticals AB reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 60,271,000 compared to SEK 43,649,000 a year ago. Operating loss was SEK 6,444,000 compared to SEK 22,479,000 a year ago. Loss after financial items was SEK 7,569,000 compared to SEK 24,179,000 a year ago. Loss was SEK 7,569,000 or SEK 0.35 per share before and after dilution compared to SEK 24,701,000 or SEK 0.53 per share before and after dilution a year ago. LBITDA was SEK 1,446,000 compared to SEK 14,348,000 a year ago. Cash flow from operating activities was SEK 8,994,000 compared to SEK 13,270,000 a year ago. For the year, on consolidated basis, the company reported net sales of SEK 187,748,000 compared to SEK 175,505,000 a year ago. Operating loss was SEK 56,102,000 compared to SEK 49,803,000 a year ago. Loss after financial items was SEK 61,377,000 compared to SEK 57,585,000 a year ago. Loss was SEK 62,519,000 or SEK 0.82 per share before and after dilution compared to SEK 58,494,000 or SEK 0.90 per share before and after dilution last year. LBITDA was SEK 34,109,000 compared to SEK 31,401,000 last year. Cash flow used in operating activities was SEK 25,632,000 compared to cash used in operating activities of SEK 29,363,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 57,259,000 compared to SEK 42,125,000 a year ago. Operating loss was SEK 7,447,000 compared to SEK 23,157,000 a year ago. Net loss was SEK 8,776,000 compared to SEK 26,230,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 185,148,000 compared to SEK 172,521,000 a year ago. Operating loss was SEK 54,217,000 compared to SEK 49,516,000 a year ago. Net loss was SEK 61,951,000 compared to SEK 58,707,000 last year.

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Company Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter and Full Year of 2014

Bluefish Pharmaceuticals AB reported consolidated and parent company earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the consolidated company reported net sales of SEK 44.671 million against SEK 41.960 million a year ago. Operating loss was SEK 13.027 million against SEK 10.858 million a year ago. Loss after financial items was SEK 14.430 million against SEK 12.644 million a year ago. Loss for the period was SEK 15.133 million against SEK 12.862 million a year ago. Loss per share after dilution was SEK 0.19 against SEK 0.18 a year ago. Cash flow used in operating activities was SEK 16.302 million against cash flow from operating activities of SEK 6.980 million a year ago. LBITDA was SEK 6.9 million against SEK 7.0 million a year ago. For the nine months, the consolidated company reported net sales of SEK 127.477 million against SEK 131.856 million a year ago. Operating loss was SEK 49.658 million against SEK 27.324 million a year ago. Loss after financial items was SEK 53.809 million against SEK 33.406 million a year ago. Loss for the period was SEK 54.873 million against SEK 33.793 million a year ago. Loss per share after dilution was SEK 0.73 against SEK 0.54 a year ago. Cash flow used in operating activities was SEK 34.625 million against cash flow from operating activities of SEK 16.092 million a year ago. LBITDA was SEK 32.7 million against SEK 17.1 million a year ago. For the quarter, the parent company reported net sales of SEK 46.671 million against SEK 41.507 million a year ago. Operating loss was SEK 9.871 million against SEK 10.169 million a year ago. Net loss for the period was SEK 12.066 million against SEK 11.953 million a year ago. For the nine months, the parent company reported net sales of SEK 127.889 million against SEK 130.396 million a year ago. Operating loss was SEK 46.770 million against SEK 26.359 million a year ago. Net loss for the period was SEK 53.175 million against SEK 32.477 million a year ago. The company expects incremental net sales of approximately SEK 15 million in the fourth quarter of 2014. This is equivalent to an increase of 35% compared to fourth quarter of 2013. The company announced that net sales growth for the full year 2014 is expected to be between 5-10%. The incremental sales is estimated to have a positive impact on profitability in the fourth quarter.

Similar Private Companies By Industry

Company Name Region
Velit Biologics Europe
Biokraft Pharma AB Europe
Apotek Produktion & Laboratorier AB Europe
Idogen AB Europe
Laccure AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.